Basic Information
| RNALocate ID: | RLID:11000685 |
| RNA Symbol: | hsa-miR-16-5p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-16 |
| RNA ID: | miRBase:MIMAT0000069 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23771658 |
| Tissue/Cell Line: | Hepatoma cells |
| Method: | Microarray|qRT-PCR |
| Description: | In line with the difference in number of detectable miRNAs, the expression levels of these miRNAs also varied between MVs and cells. Statistical analysis of the 148 co-expressing miRNAs showed that 25 miRNAs were aberrantly elevated inMVs and 75 miRNAs were significantly elevated in cells with more than two folds change. Forty-eight miRNAs had the similar signal intensity in both groups (table 1). Data are collected from Table 1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001255 | Cytoplasm | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001256 | Cytoplasm | Cell line (HeLa) | 21695135 |
| RLID:01001257 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001258 | Mitochondrion | Osteosarcoma cell line (143B) | 27396686 |
| RLID:01001259 | Mitochondrion | Osteosarcoma cell line (143B) | 27563705 |
| RLID:01001260 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001261 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001262 | Nucleolus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001263 | Nucleus | GC cell line (MGC-803) | 29872807 |
| RLID:01001264 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:01001265 | Nucleus | Neural progenitor cells | 21363885 |
| RLID:01001266 | Polysome | Human cervical cancer cell line (HeLa) | 25609084 |
| RLID:11000667 | Exosome | Pooled sera | 27278097 |
| RLID:11000668 | Exosome | EBV- and KSHV-negative Burkitt lymphoma cell line (Bjab)|EBV-infected lymphoblastoid cell line (LCL)|KSHV-infected lymphoma cell lines (BCBL-1|TY-1) | 27611973 |
| RLID:11000669 | Exosome | Plasma | 30154547 |
| RLID:11000670 | Exosome | Glioblastoma cells | 19011622 |
| RLID:11000671 | Exosome | Human embryonic kidney cell line (HEK-293) | 20353945 |
| RLID:11000672 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11000673 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
| RLID:11000674 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11000675 | Exosome | Brain tissue | 23382797 |
| RLID:11000676 | Exosome | Plasma | 23663360 |
| RLID:11000677 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11000678 | Exosome | Plasma | 24130905 |
| RLID:11000679 | Exosome | Breast cancer cell lines (MCF-7|MDA-MB-231) | 24468161 |
| RLID:11000680 | Extracellular Vesicle | Plasma | 28588009 |
| RLID:11000681 | Microvesicle | Glioblastoma cells | 19011622 |
| RLID:11000682 | Microvesicle | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11000683 | Microvesicle | Plasma | 23077538 |
| RLID:11000684 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000008 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Colon tissue|Endothelial cells|Epithelial cells|Kidney tissue|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue | |
| RLID-D:11000268 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-16-5p | Alk+ anaplastic large-cell lymphoma | MNDR-E-MI-18717 |
| MNDR | hsa-miR-16-5p | Mantle cell lymphoma | MNDR-E-MI-18718 |
| MNDR | hsa-miR-16-5p | Splenic marginal zone lymphoma | MNDR-E-MI-18719 |
| MNDR | hsa-miR-16-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-18720 |
| MNDR | hsa-miR-16-5p | Oral squamous cell carcinoma | MNDR-E-MI-18721 |
| MNDR | hsa-miR-16-5p | Medulloblastoma | MNDR-E-MI-18722 |
| MNDR | hsa-miR-16-5p | B cell lymphoma of malt type | MNDR-E-MI-18723 |
| MNDR | hsa-miR-16-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-18724 |
| MNDR | hsa-miR-16-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-18725 |
| MNDR | hsa-miR-16-5p | Lymphoma | MNDR-E-MI-18726 |
| MNDR | hsa-miR-16-5p | Lymphoma non-hodgkin | MNDR-E-MI-18727 |
| MNDR | hsa-miR-16-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-18728 |
| MNDR | hsa-miR-16-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-18729 |
| MNDR | hsa-miR-16-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-18730 |
| MNDR | hsa-miR-16-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-18731 |
| MNDR | hsa-miR-16-5p | Her2-receptor positive breast cancer | MNDR-E-MI-18732 |
| MNDR | hsa-miR-16-5p | Breast cancer luminal | MNDR-E-MI-18733 |
| MNDR | hsa-miR-16-5p | Niemann-pick disease type c | MNDR-E-MI-18734 |
| MNDR | hsa-miR-16-5p | Prostate cancer | MNDR-E-MI-18735 |
| MNDR | hsa-miR-16-5p | B-cell chronic lymphocytic leukemia | MNDR-E-MI-18736 |
| MNDR | hsa-miR-16-5p | Gastric cancer | MNDR-E-MI-18737 |
| MNDR | hsa-miR-16-5p | Gastric lymphoma | MNDR-E-MI-18738 |
| MNDR | hsa-miR-16-5p | Alzheimer disease | MNDR-E-MI-18739 |
| MNDR | hsa-miR-16-5p | Intracranial aneurysm | MNDR-E-MI-18740 |
| MNDR | hsa-miR-16-5p | Dysautonomia familial | MNDR-E-MI-18741 |
| MNDR | hsa-miR-16-5p | Malaria | MNDR-E-MI-18742 |
| MNDR | hsa-miR-16-5p | Ataxia telangiectasia | MNDR-E-MI-18743 |
| MNDR | hsa-miR-16-5p | Huntington disease | MNDR-E-MI-18744 |
| MNDR | hsa-miR-16-5p | Chorea | MNDR-E-MI-18745 |
| MNDR | hsa-miR-16-5p | Cardiovascular disease | MNDR-E-MI-18746 |
| MNDR | hsa-miR-16-5p | Moyamoya disease | MNDR-E-MI-18747 |
| MNDR | hsa-miR-16-5p | Lung cancer | MNDR-E-MI-18748 |
| MNDR | hsa-miR-16-5p | Down syndrome | MNDR-E-MI-18749 |
| MNDR | hsa-miR-16-5p | Parkinson disease | MNDR-E-MI-18750 |
| MNDR | hsa-miR-16-5p | Niemann-pick disease | MNDR-E-MI-18751 |
| MNDR | hsa-miR-16-5p | Basal-like breast cancer | MNDR-E-MI-18752 |
| MNDR | hsa-miR-16-5p | Cancer | MNDR-E-MI-18753 |
| MNDR | hsa-miR-16-5p | Pituitary neoplasms | MNDR-E-MI-18754 |
| MNDR | hsa-miR-16-5p | Pancreatic cancer | MNDR-E-MI-18755 |
| MNDR | hsa-miR-16-5p | Melanoma | MNDR-E-MI-18756 |
| MNDR | hsa-miR-16-5p | Gaucher disease | MNDR-E-MI-18757 |
| MNDR | hsa-miR-16-5p | Rectum adenocarcinoma | MNDR-E-MI-18758 |
| MNDR | hsa-miR-16-5p | Colon cancer | MNDR-E-MI-18759 |
| MNDR | hsa-miR-16-5p | Ischemic attack transient | MNDR-E-MI-18760 |
| MNDR | hsa-miR-16-5p | Colon adenocarcinoma | MNDR-E-MI-18761 |
| MNDR | hsa-miR-16-5p | Multiple sclerosis | MNDR-E-MI-18762 |
| MNDR | hsa-miR-16-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-18763 |
| MNDR | hsa-miR-16-5p | Familial ovarian cancer | MNDR-E-MI-18764 |
| MNDR | hsa-miR-16-5p | Laryngeal carcinoma | MNDR-E-MI-18765 |
| MNDR | hsa-miR-16-5p | Carcinoma ductal breast | MNDR-E-MI-18766 |
| MNDR | hsa-miR-16-5p | Glioblastoma | MNDR-E-MI-18767 |
| MNDR | hsa-miR-16-5p | Astrocytoma | MNDR-E-MI-18768 |
| MNDR | hsa-miR-16-5p | Glioma | MNDR-E-MI-18769 |
| MNDR | hsa-miR-16-5p | Chronic obstructive pulmonary disease | MNDR-E-MI-18770 |
| MNDR | hsa-miR-16-5p | Oligodendroglioma | MNDR-E-MI-18771 |
| MNDR | hsa-miR-16-5p | Chordoma | MNDR-E-MI-18772 |
| MNDR | hsa-miR-16-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-18773 |
| MNDR | hsa-miR-16-5p | Epilepsy temporal lobe | MNDR-E-MI-18774 |
| MNDR | hsa-miR-16-5p | Osteosarcoma | MNDR-E-MI-18775 |
| MNDR | hsa-miR-16-5p | Liposarcoma | MNDR-E-MI-18776 |
| MNDR | hsa-miR-16-5p | Coronary artery disease | MNDR-E-MI-18777 |
| MNDR | hsa-miR-16-5p | Breast carcinoma | MNDR-E-MI-18778 |
| MNDR | hsa-miR-16-5p | Infarction middle cerebral artery | MNDR-E-MI-18779 |
| MNDR | hsa-miR-16-5p | Cerebral infarction | MNDR-E-MI-18780 |
| MNDR | hsa-miR-16-5p | Liver cancer | MNDR-E-MI-18781 |
| MNDR | hsa-miR-16-5p | Cervical adenocarcinoma | MNDR-E-MI-18782 |
| MNDR | hsa-miR-16-5p | Gastric adenocarcinoma | MNDR-E-MI-18783 |
| MNDR | hsa-miR-16-5p | Cervical squamous cell carcinoma | MNDR-E-MI-18784 |
| MNDR | hsa-miR-16-5p | Pituitary adenoma | MNDR-E-MI-18785 |
| MNDR | hsa-miR-16-5p | Lung squamous cell carcinoma | MNDR-E-MI-18786 |
| MNDR | hsa-miR-16-5p | Carcinoma lung non small cell | MNDR-E-MI-18787 |
| MNDR | hsa-miR-16-5p | Adrenocortical cancer | MNDR-E-MI-18788 |
| MNDR | hsa-miR-16-5p | Thyroid carcinoma | MNDR-E-MI-18789 |
| MNDR | hsa-miR-16-5p | Papillary thyroid carcinoma | MNDR-E-MI-18790 |
| MNDR | hsa-miR-16-5p | Ovarian carcinoma | MNDR-E-MI-18791 |
| MNDR | hsa-miR-16-5p | Bladder urothelial carcinoma | MNDR-E-MI-18792 |
| MNDR | hsa-miR-16-5p | Pancreatic adenocarcinoma | MNDR-E-MI-18793 |
| MNDR | hsa-miR-16-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-18794 |
| MNDR | hsa-miR-16-5p | Carcinoma renal cell | MNDR-E-MI-18795 |
| MNDR | hsa-miR-16-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-18796 |
| MNDR | hsa-miR-16-5p | Clear cell renal cell carcinoma | MNDR-E-MI-18797 |
| MNDR | hsa-miR-16-5p | Biliary tract cancer | MNDR-E-MI-18798 |
| MNDR | hsa-miR-16-5p | Cholangiocarcinoma | MNDR-E-MI-18799 |
| MNDR | hsa-miR-16-5p | Esophageal cancer | MNDR-E-MI-18800 |
| MNDR | hsa-miR-16-5p | Lung small cell carcinoma | MNDR-E-MI-18801 |
| MNDR | hsa-miR-16-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-18802 |
| MNDR | hsa-miR-16-5p | Testicular germ cell cancer | MNDR-E-MI-18803 |
| MNDR | hsa-miR-16-5p | Heart failure | MNDR-E-MI-18804 |
| MNDR | hsa-miR-16-5p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-18805 |
| MNDR | hsa-miR-16-5p | Breast invasive carcinoma | MNDR-E-MI-18806 |
| MNDR | hsa-miR-16-5p | Juvenile rheumatoid arthritis | MNDR-E-MI-18807 |
| MNDR | hsa-miR-16-5p | Hepatocellular carcinoma | MNDR-E-MI-18808 |
| MNDR | hsa-miR-16-5p | Familiar ovarian carcinoma | MNDR-E-MI-18809 |
| MNDR | hsa-miR-16-5p | B-cell lymphoma | MNDR-E-MI-18810 |
| MNDR | hsa-miR-16-5p | Rheumatoid arthritis | MNDR-E-MI-18811 |
| MNDR | hsa-miR-16-5p | T-cell leukemia | MNDR-E-MI-18812 |
| MNDR | hsa-miR-16-5p | Neuroblastoma | MNDR-E-MI-18813 |
| MNDR | hsa-miR-16-5p | Osteoarthritis | MNDR-E-MI-18814 |
| MNDR | hsa-miR-16-5p | Hodgkin lymphoma | MNDR-E-MI-18815 |
| MNDR | hsa-miR-16-5p | Ulcerative colitis | MNDR-E-MI-18816 |
| MNDR | hsa-miR-16-5p | Burkitt lymphoma | MNDR-E-MI-18817 |
| MNDR | hsa-miR-16-5p | Crohn disease | MNDR-E-MI-18818 |
| MNDR | hsa-miR-16-5p | Neuromyelitis optica | MNDR-E-MI-18819 |
| MNDR | hsa-miR-16-5p | Skin cutaneous melanoma | MNDR-E-MI-18820 |
| MNDR | hsa-miR-16-5p | Skin melanoma | MNDR-E-MI-18821 |
| MNDR | hsa-miR-16-5p | Acute myelogenous leukemia | MNDR-E-MI-18822 |
| MNDR | hsa-miR-16-5p | Colorectal cancer | MNDR-E-MI-18823 |
| MNDR | hsa-miR-16-5p | Type 2 diabetes mellitus | MNDR-E-MI-18824 |
| MNDR | hsa-miR-16-5p | Multiple myeloma | MNDR-E-MI-18825 |
| MNDR | hsa-miR-16-5p | Serous ovarian cancer | MNDR-E-MI-18826 |
| MNDR | hsa-miR-16-5p | Ependymoma | MNDR-E-MI-18827 |
| MNDR | hsa-miR-16-5p | Hearing loss noise-induced | MNDR-E-MI-18828 |
| MNDR | hsa-miR-16-5p | Nasopharyngeal cancer | MNDR-E-MI-18829 |
| MNDR | hsa-miR-16-5p | Prostatic neoplasms | MNDR-E-MI-18830 |
| MNDR | hsa-miR-16-5p | Pseudorabies | MNDR-E-MI-18831 |
| MNDR | hsa-miR-16-5p | Sleep deprivation | MNDR-E-MI-18832 |
| MNDR | hsa-miR-16-5p | Hypersomnolence idiopathic | MNDR-E-MI-18833 |
| MNDR | hsa-miR-16-5p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-18834 |
| MNDR | hsa-miR-16-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-18835 |
| MNDR | hsa-miR-16-5p | Pituitary acth hypersecretion | MNDR-E-MI-18836 |
| MNDR | hsa-miR-16-5p | Stroke lacunar | MNDR-E-MI-18837 |
| MNDR | hsa-miR-16-5p | Breast cancer her3+ negative | MNDR-E-MI-18838 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCB1 | Homo sapiens | RR00022775 |
TOP